Kailera Therapeutics, Inc.
KLRA
Positions held
Your positionsKLRA isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- Kailera Therapeutics operates in the biotechnology sector, which is known for its potential to innovate and address unmet medical needs, making it an attractive long-term investment.
- The company's market cap is approximately $1.4 billion, indicating significant investor interest and potential for growth.
- Analysts have a strong buy recommendation for KLRA, with a target mean price of $42.4, suggesting substantial upside from current levels.
- Kailera Therapeutics has reported zero revenue for multiple quarters, highlighting a critical challenge in achieving commercial viability.
- The company has consistently posted negative net income, with losses reaching -111.307 million in Q2 2026.
- KLRA's current score is -6.00, indicating a sell signal based on technical analysis and market trends.
Fundamentals
| Market cap | $1.30B | Enterprise value | $389.91M | Trailing P/E | — | Forward P/E | -2.33 |
| PEG | — | Price / book | 1.16 | Beta | — | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 0.0% | Operating margin | 0.0% |
| Profit margin | 0.0% | ROE | — | ROA | — | Debt / equity | 0.01 |
| Current ratio | 11.11 | Free cash flow | — | Analyst recommendation | strong_buy | Mean target | $42.40 |
| 52w high | $28.23 | 52w low | $9.76 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M |
| Op margin | — | — | — | — |
| Net income | -$111M | -$78.9M | -$28.9M | -$18.0M |
| Gross margin | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | -$121M | -$84.7M | -$30.7M | -$20.5M |
Yearly (6y)
| 2025 | |
|---|---|
| Revenue | $0.0M |
| Op margin | — |
| Net income | -$149M |
| Gross margin | — |
| Gross profit | — |
| Operating income | -$158M |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-01 · Kailera Therapeutics Presents New Clinical Data at EASD 2026 Annual Meeting
2026-09-30 · Novo Is Open to Acquisitions. Here Are 2 Companies That Would Be Great Candidates to Buy
2026-09-30 · Kailera Therapeutics Completes Enrollment for Trial of Ribupatide to Treat Obesity
2026-09-16 · Kailera Therapeutics to Participate in September Investor Conferences
2026-09-15 · Jim Cramer Calls Kailera Therapeutics (KLRA) “The Most Speculative Stock On Earth”
2026-08-18 · Kailera Therapeutics: The Record-Breaking Obesity IPO Big Pharma Cannot Ignore
2026-08-17 · Kailera Therapeutics (KLRA) Reports Wider Losses And Names New CTO, Is The Low P B Justified?
2026-08-16 · 2 GLP-1 Stocks That Could Double Your Money by 2031
2026-08-12 · Kailera Reports Second Quarter 2026 Financial Results and Provides Business Updates
2026-08-11 · Kailera Therapeutics Appoints Nur Nicholson as Chief Technology Officer
2026-07-15 · 2 Beaten-Down GLP-1 Stocks to Buy on the Dip
Price (daily)
Full chart · RSI · MACD · patterns